1. Home
  2. MDXH vs NXC Comparison

MDXH vs NXC Comparison

Compare MDXH & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
    SELLHOLDBUYas of 2 hours ago
  • NXC
    SELLHOLDBUYas of 2 hours ago
  • Stock Information
  • Founded
  • MDXH 2003
  • NXC 1992
  • Country
  • MDXH Belgium
  • NXC United States
  • Employees
  • MDXH N/A
  • NXC N/A
  • Industry
  • MDXH
  • NXC Investment Managers
  • Sector
  • MDXH
  • NXC Finance
  • Exchange
  • MDXH Nasdaq
  • NXC Nasdaq
  • Market Cap
  • MDXH 93.1M
  • NXC 87.3M
  • IPO Year
  • MDXH 2021
  • NXC N/A
  • Fundamental
  • Price
  • MDXH $2.13
  • NXC $13.11
  • Analyst Decision
  • MDXH Strong Buy
  • NXC
  • Analyst Count
  • MDXH 2
  • NXC 0
  • Target Price
  • MDXH $7.00
  • NXC N/A
  • AVG Volume (30 Days)
  • MDXH 147.6K
  • NXC 17.5K
  • Earning Date
  • MDXH 11-06-2024
  • NXC 01-01-0001
  • Dividend Yield
  • MDXH N/A
  • NXC 3.97%
  • EPS Growth
  • MDXH N/A
  • NXC N/A
  • EPS
  • MDXH N/A
  • NXC 0.19
  • Revenue
  • MDXH $84,708,000.00
  • NXC N/A
  • Revenue This Year
  • MDXH $27.57
  • NXC N/A
  • Revenue Next Year
  • MDXH $20.09
  • NXC N/A
  • P/E Ratio
  • MDXH N/A
  • NXC $70.47
  • Revenue Growth
  • MDXH 33.01
  • NXC N/A
  • 52 Week Low
  • MDXH $1.55
  • NXC $11.86
  • 52 Week High
  • MDXH $4.64
  • NXC $13.70
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 50.43
  • NXC 46.39
  • Support Level
  • MDXH $2.09
  • NXC $13.15
  • Resistance Level
  • MDXH $2.52
  • NXC $13.29
  • Average True Range (ATR)
  • MDXH 0.15
  • NXC 0.14
  • MACD
  • MDXH -0.00
  • NXC -0.01
  • Stochastic Oscillator
  • MDXH 41.85
  • NXC 42.19

Stock Price Comparison Chart: MDXH vs NXC

MDXH
NXC
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober02468101214161820MDXH VS NXC

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

About NXC Nuveen California Select Tax-Free Income Portfolio

Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use